Vertebral body defects treated with umbilical-cord mesenchymal stem cells combined with hydroxyapatite scaffolds: The first case report
- PMID: 31901558
- PMCID: PMC6940685
- DOI: 10.1016/j.ijscr.2019.12.002
Vertebral body defects treated with umbilical-cord mesenchymal stem cells combined with hydroxyapatite scaffolds: The first case report
Abstract
Introduction: Vertebral body defects (VBDs) are one of the most frequent orthopaedic disorders. Such defects often require bone grafts or fusion procedures; however, both procedures often fail due to various factors. Mesenchymal stem cells (MSCs) have been used as a potential therapy to fill bone voids in bone defects, and they may be a potential treatment for VBDs. We reported VBDs treated with MSCs combined with hydroxyapatite scaffolds.
Presentation of case: A 27-year-old female presented with recurrent back pain. She had a history of decompression and stabilization procedure one year ago after diagnosed with spinal tuberculosis. Initially, she felt back pain that intensifies with activity and relieved with rest. She noticed that the pain begun when once she heard a crack sound on her back while trying to get up from sitting position. There was no history of numbness or tingling sensation. There were no walking problems. Other functions, including micturition and defecation, were within normal limits. The patient firstly underwent lumbotomy procedure, and the images were all confirmed with fluoroscopy X-ray. The vertebrae went debridement, and finally, the bone defect was filled with 20 millions of umbilical cord-mesenchymal stem cells (UC-MSCs) combined with hydroxyapatite in 2 cc of saline.
Discussion: At three months postoperative, the patient could walk and had no pain. At six months of follow-up, no complications occurred. We also did not see any signs of neoplasm formation, which is consistent with previous studies that used MSCs for orthopaedic treatment. Moreover, no significant bone deformation or spinal cord compression was observed, which suggested the safety of the transplantation procedure.
Conclusions: We found that MSCs combined with hydroxyapatite represents a potential therapy for bone regeneration in VBD. Further clinical studies are required to investigate the safety and efficacy of this combination of therapy in VBDs.
Keywords: Hydroxyapatite; Mesenchymal stem cells; Vertebral body defects.
Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest None.
Figures





Similar articles
-
Integration of Umbilical Cord Mesenchymal Stem Cell Application in Hydroxyapatite-Based Scaffolds in the Treatment of Vertebral Bone Defect due to Spondylitis Tuberculosis: A Translational Study.Stem Cells Int. 2021 Aug 23;2021:9928379. doi: 10.1155/2021/9928379. eCollection 2021. Stem Cells Int. 2021. PMID: 34475959 Free PMC article.
-
Modified Masquelet technique using allogeneic umbilical cord-derived mesenchymal stem cells for infected non-union femoral shaft fracture with a 12 cm bone defect: A case report.Int J Surg Case Rep. 2017;34:11-16. doi: 10.1016/j.ijscr.2017.03.002. Epub 2017 Mar 6. Int J Surg Case Rep. 2017. PMID: 28324799 Free PMC article.
-
Regeneration of the rotator cuff tendon-to-bone interface using umbilical cord-derived mesenchymal stem cells and gradient extracellular matrix scaffolds from adipose tissue in a rat model.Acta Biomater. 2020 Sep 15;114:104-116. doi: 10.1016/j.actbio.2020.07.020. Epub 2020 Jul 15. Acta Biomater. 2020. PMID: 32682057
-
Pediatric cervical kyphosis in the MRI era (1984-2008) with long-term follow up: literature review.Childs Nerv Syst. 2022 Feb;38(2):361-377. doi: 10.1007/s00381-021-05409-z. Epub 2021 Nov 22. Childs Nerv Syst. 2022. PMID: 34806157 Review.
-
Bone and cartilage regeneration with the use of umbilical cord mesenchymal stem cells.Expert Opin Biol Ther. 2015;15(11):1541-52. doi: 10.1517/14712598.2015.1068755. Epub 2015 Jul 15. Expert Opin Biol Ther. 2015. PMID: 26176327 Review.
Cited by
-
Cross-Talk Between Mesenchymal Stromal Cells (MSCs) and Endothelial Progenitor Cells (EPCs) in Bone Regeneration.Front Cell Dev Biol. 2021 May 13;9:674084. doi: 10.3389/fcell.2021.674084. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 34079804 Free PMC article. Review.
References
-
- Tzioupis C., Giannoudis P.V. Prevalence of long-bone non-unions. Injury. 2007;38(Suppl 2):S3–S9. - PubMed
-
- Boden S.D. Biology of lumbar spine fusion and use of bone graft substitutes: present, future, and next generation. Tissue Eng. 2000;6(4):383–399. - PubMed
-
- Green E., Lubahn J.D., Evans J. Risk factors, treatment, and outcomes associated with nonunion of the midshaft humerus fracture. J. Surg. Orthop. Adv. 2005;14(2):64–72. - PubMed
-
- Kanakaris N.K., Giannoudis P.V. The health economics of the treatment of long-bone non-unions. Injury. 2007;38(Suppl 2):S77–S84. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials